# Zymeworks Inc. (ZYME)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.73B  
**Price:** $22.96 (+0.50%)

> Zymeworks Inc. is a biotechnology company that focuses on innovating biotherapeutics for the treatment of cancer and autoimmune diseases. The company's core mission revolves around developing novel, multifunctional therapeutics with the potential to improve efficacy and reduce side effects compared to conventional cancer treatments. Zymeworks utilizes its proprietary platforms, such as the Azymetric and EFECT technologies, which enable the creation of multifunctional antibody therapeutics. These assets are significant in sectors such as oncology and immunology, addressing unmet needs with therapies aimed at complex and difficult-to-treat conditions. Based in Canada, Zymeworks collaborates with leading global pharmaceutical companies to enhance the reach and impact of its research. In the financial market, Zymeworks Inc. is notable for its strategic partnerships and potential for contributing to advancements in precision medicine, emphasizing its role not only in scientific innovation but also as a key player in the biotech industry's approach to personalized healthcare solutions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $106M | — | -$93M | -$81M | — |
| 2024 | $76M | — | -$137M | -$123M | — |
| 2023 | $76M | — | -$138M | -$119M | — |
| 2022 | $412M | — | $131M | $124M | — |
| 2021 | $27M | — | -$216M | -$212M | — |
| 2020 | $39M | — | -$187M | -$181M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $347M | $78M | $269M | $41M | — |
| 2024 | $463M | $124M | $339M | $66M | — |
| 2023 | $581M | $116M | $465M | $158M | — |
| 2022 | $649M | $156M | $493M | $401M | — |
| 2021 | $389M | $140M | $249M | $202M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$33M | $2M | -$35M |
| 2024 | -$110M | $2M | -$112M |
| 2023 | -$118M | $2M | -$121M |
| 2022 | $144M | $8M | $136M |
| 2021 | -$192M | $12M | -$205M |
| 2020 | -$151M | $4M | -$156M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ZYME)